The feasibility of synthetic enhancer substances for preventive nanotherapy;Preventív nanoterápiás lehetoségek szintetikus enhancer anyagokkal

Neuropsychopharmacologia Hungarica

Volumn 12, Issue 3, 2010, Pages 395-403

  Ildikó, Miklya ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

( ) BPAP; ( ) Deprenyl selegiline; Enhancer regulation; Enhancer substances; Nanotherapy

Indexed keywords

1 (BENZOFURAN 2 YL) 2 PROPYLAMINOPENTANE; BENZOFURAN DERIVATIVE; LIPOSOME; SELEGILINE; UNCLASSIFIED DRUG;

ADULT; ALZHEIMER DISEASE; CASE REPORT; CATECHOLAMINE NERVE CELL; DEPRESSION; DRUG MECHANISM; ENHANCER REGION; HUMAN; MEDICAL RESEARCH; NANOTECHNOLOGY; PARKINSON DISEASE; REVIEW; SEROTONINERGIC NERVE CELL; SIGNAL TRANSDUCTION; TARGET CELL;

ALZHEIMER DISEASE; ANIMALS; BRAIN STEM; CATECHOLAMINES; DEPRESSIVE DISORDER; FEASIBILITY STUDIES; HUMANS; LIPOSOMES; NANOMEDICINE; NEURONS; NOOTROPIC AGENTS; PARKINSON DISEASE; PREVENTIVE MEDICINE; SELEGILINE; SEROTONIN; UBIQUITIN-PROTEIN LIGASES;

EID: 78651356211     PISSN: 14198711     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Amenta F, Bongrani S, Cadel S, Ricci A, Valsecchi B, Zeng YC (1994) Neuroanatomy of aging brain. Influence of treatment with L-deprenyl. Ann NY Acad Sci 717:33-44.
2. Allain H, Gougnard J, Naukirek HC (1991) Selegiline in de novo parkinsonian patients: the French selegiline multicenter trial (FSMP). Acta Neurol Scand 136:73-78.
3. Amsterdam JD (2003) A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 64:208-214.
4. Berry MD, Juorio AV, Paterson IA (1994) Possible mechanisms of action of (-)-deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders. Progr in Neurobiology 44:141-161.
5. Bertocci B, Gill G, Da Prada M (1988) Prevention of the DSP-4 induced noradrenergic neurotoxicity by irreversible, not by reversible MAO-B inhibitors. Pharmacol Res Comm Suppl 20:131-132. (Pubitemid 19040622)
6. BirkmayerW, Riederer P, Ambrozi L, Youdim MBH (1977) Implications of combined treatment with 'Madopar' and L-deprenyl in Parkinson's disease. Lancet 1:439-443.
7. Boulton AA (1976) Cerebral aryl alkyl aminergic mechanisms. In: Trace amines and the brain, Eds.: Usdin E, Sandler M, pp:21-39, Marcel Dekker, New York.
8. Boulton AA (1978) The tyramines: Functionally significant amines or metabolic accidents? Life Sci 23:659-672.
9. Buys YM, Trope GE, Tatton WG (1995) (-)-Deprenyl increases the survival of rat retinal ganglion cells after optic nerve crush. Curr Eye Res 14:119-26.
10. Campi N, Todeschini GP, Scarzella L (1990) Selegiline versus L-acetylcarnitine in the treatment of Alzheimer-type dementia. Clin Ther 12:306-314. (Pubitemid 20287912)
11. Carillo MC, Kanai S, Nokubo M, Kitani K (1991) (-)Deprenyl induces activities of both superoxide dismutase and catalase but not of glutatione peroxidase in the striatum of young male rats. Life Sci 48:517-521.
12. De la Cruz CP, Revilla E, Rodriguez-Gomez JA, Vizuete ML, Cano J, Machado A (1997) Deprenyl treatment restores serum insuline-like growth factor - I (IGF-I) levels in aged rats to young rat level. Eur J Pharmacol 327:215-220. (Pubitemid 27248548)
13. Denes L, Szilágyi G, Gál A, Bori Z, Nagy Z (2006) Cytoprotective effect of two synthetic enhancer substances, (-)-BPAP and (-)-deprenyl, on human brain capillary endothelial cells and rat PC12 cells. Life Sci 79:1034-1039. (Pubitemid 44067061)
14. Esmaeili F, Tiraihi T, Movahedin M, Mowia SJ (2006) Selegiline induces neuronal phenotype and neurotrophines expression in embrionic stem cells. Rejuvenation Res 9:475-484. (Pubitemid 46100669)
15. Falsaperle A, Monici Preti PA, Oliani C (1990) Selegiline versus oxiracetam in patients with Alzheimer-type dementia. Clin Ther 12:376-384.
16. Feynmann RP (1959) Plenty of Room at the Bottom. Presentation to American Physical Society.
17. Finnegan KT, Skratt JJ, Irvin I, DeLanney LE, Langston JW (1990) Protection against DSP-4 induced neurotoxicity by deprenyl is not related to its inhibition of MAO-B. Eur J Pharmacol 184:119-126.
18. Gaszner P (1991) On cognition-enhancing properties of antidepressants (including selegiline). In: Biological Psychiatry Vol 2, pp:169-171, Eds.: Racagni G et al., Elsevier Science Publishers B V.
19. Gaszner P, Miklya I (2006) Major depression and the synthetic enhancer substances, (-)-deprenyl and R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane. Prog Neuro-Psychopharmacol Biol Psych 30:5-14.
20. Glover V, Sandler M (1993) Neurotoxins and monoamine oxidase B inhibitors: Possible mechanism for the neuroprotective effect of (-)-deprenyl. In: Inhibitors of Monoamine oxidase. Ed.: Szelényi I, pp:169-182, Birkhauser Verlag, Basel.
21. Gupta S, Droney T, Kyser A, Keller P (1999) Selegiline augmentation of antipsychotics for the treatment of negative symptoms in schizophrenia. Comp Psychiatry 40:148-150. (Pubitemid 29108626)
22. Gupta M, Kulkarni SK (2000) Studies on anticonvulsant actions of L-deprenyl. Indian J Exp Biol 38:332-337.
23. Hamabe W, Fujita R, Yasusa T, Yoneda F, Yoshida A, Ueda H (2000) (-)1-(Benzofuran-2-yl)-2-propylaminopentane shows survival effect on cortical neurons under serum-free condition through sigma receptors. Cell Mol Neurobiol 20:695-702.
24. Hársing LG, Magyar K, Tekes K, Vizi ES, Knoll J (1979) Inhibition by deprenyl of dopamine uptake in rat striatum: a possible correlation between dopamine uptake and acetylcholine. Pol J Pharmacol Pharm 31:297-307. (Pubitemid 10213750)
25. Hirami C, Takahata K, Shimazu S, Yoneda F, Hayashi K, Katsuki H, Akaike A (2005) Effects of R-(-)-BPAP on the expressions of neurotrophins and their receptors in mesencephalic slices. Biol Pharm Bull 28:1524-1526. (Pubitemid 41379713)
26. Hiranita T, Yamamoto T, Nawata Y (2010) A tryptamine-derived catecholaminergic enhancer, (-)-1-(benzofuran-2-yl)-2-propylaminopentane [(-)-BPAP], attenuates reinstatement of methamphetamine-seeking behavior in rats. Neurosience 165:300-312.
27. Jankovic J (1993) Deprenyl in attention deficit associated with Tourette's syndrome. Arch Neurol 50:268-288.
28. Kiray M, Bagriyanik HA, Pekcetin C, Ergur BU, Uysal N, Ozyurt D, Buldan Z (2006) Deprenyl and the relationship between its effects on spatial memory, oxidant stress and hippocampal neurons in aged male rats. Physiol Res 55:205-212.
29. Kitani K, Kanai S, Sato Y, Ohta M, Ivy GO, Carillo MC (1992) Chronic treatment of (-)deprenyl prolongs the lifespan of male Fischer 344 rats. Further evidence. Life Sci 52:281-288.
30. Knoll J (1978) The possible mechanism of action of (-)deprenyl in Parkinson's disease. J Neural Transm 43:177-198. (Pubitemid 9050079)
31. Knoll J (1988) The striatal dopamine dependency of lifespan in male rats. longevity study with (-)deprenyl. Mech Ageing Dev 46:237-262.
32. Knoll J (1989) The pharmacology of selegiline ((-)deprenyl). New aspects. Acta Neurol Scand 126:83-91.
33. Knoll J (1994) Memories of my 45 years in research. Pharmacol Toxicol 75:65-72.
34. Knoll J (1998) (-)Deprenyl (Selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain. Pharmacol & Toxicol 82:57-66.
35. Knoll J (2000) Outlines of a drug strategy to slow brain aging. Neuropsychopharmacologia Hungarica 4:151-170, 2000.
36. Knoll J (2003) Enhancer regulation/endogenous and synthetic enhancer compounds: A neurochemical concept of the innate and acquired drives. Neurochem Res 28:1275-1297.
37. Knoll J (2006) Az agy és tudata. A veleszületett és szerzett hajtóerocombining double acute accentk neurokémiai koncepciója. Akadémiai Kiadó, Budapest, 266 oldal.
38. Knoll J, Magyar K (1972) Some puzzling effects of monoamine oxidase inhibitors, In: Monoamine Oxidase-New Vistas. Advances in Biochemical Psychopharmacology. Vol.5. (Eds.: Costa E, Sandler M), Raven Press, New York, pp 393-408.
39. Knoll J, Miklya I (1994) Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition. Arch int Pharmacodyn Thér 328:1-15. (Pubitemid 24353343)
40. Knoll J, Miklya I (1995) Enchanced catecholaminergic and serotoninergic activity in rat brain from weaning to sexual maturity: Rationale for prophylactic (-) deprenyl (selegiline) medication. Life Sci 56:611-620.
41. Knoll J, Ecsery Z, Nievel J, Knoll B (1964) Phenylisopropylmethyl- propinylamine HCL (E-250) egy új hatásspektrumú pszichoenergetikum. MTA V. Oszt Közl 15: 231-238.
42. Knoll J, Ecsery Z, Kelemen K, Nievel J, Knoll B (1965) Phenylisopropylmethyl-propinylamine (E-250) a new psychic energizer. Arch int Pharmacodyn Thér 155:154-164.
43. Knoll J, Vizi ES, Somogyi G (1968) Phenylisopropylmethylpropinylamine (E-250), a monoamine oxidase inhibitor antagonizing the effects of tyramine. Arzneimittelforsch 18:109-112
44. Knoll J, Dalló J, Yen TT (1989) Striatal dopamine, sexual activity and lifespan. Longevity of rats treated with (-)deprenyl. Life Sci 45:525-531.
45. Knoll B, Yasar S, Faragó I, Kovács I, Knoll J (1990) 1-Phenyl-2-propyl-aminopentane.HCL (MK-306): A deprenyl-derived new spectrum psychostimulant. Eur J Pharmacol 183:1464. (Pubitemid 20243054)
46. Knoll J, Knoll B, Török Z, Tímár J, Yasar S (1992a) The pharmacology of 1-phenyl-2-propylaminopentane (PPAP), a deprenyl-derived new spectrum psychostimulant. Arch int Pharmacodyn Thér 316:5-29.
47. Knoll J, Tóth V, Kummert M, Sugár J (1992b) (-)Deprenyl and (-)parafluorodeprenyl-treatment prevents age-related pigment changes in the substantia nigra. A TV-image analysis of neuromelaninn. Mech Ageing Dev 63, 157-163.
48. Knoll J, Yen TT, Miklya I (1994) Sexually low performing male rats dies earlier than their high performing peers and (-) deprenyl treatment eliminates this difference. Life Sci. 54:1047-1057. (Pubitemid 24125007)
49. Knoll J, Miklya I, Knoll B, Markó R, Kelemen K (1996a) (-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants of action potential-transmitter release coupling in the catecholaminergic neurons. Life Sci 58:817-827.
50. Knoll J, Knoll B, Miklya I (1996b) High performing rats are more sensitive toward catecholaminergic activity enhancer (CAE) compounds than their low performing peers. Life Sci 58:945-952. (Pubitemid 26075563)
51. Knoll J, Miklya I, Knoll B, Markó R, Rácz D (1996c) Phenylethylamine and tyramine are mixed-acting sympathomimetic amines in the brain. Life Sci 58:2101-2114. (Pubitemid 26168549)
52. Knoll J, Yoneda F, Knoll B, Ohde H, Miklya I (1999) (-)1-(Benzofuran-2- yl)-2-propylaminopentane, (-)BPAP, a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. Brit J Pharmacol 128:1723-1732. (Pubitemid 30011886)
53. Knoll J, Miklya I, Knoll B (2002) Stimulation of the catecholaminergic and serotoninergic neurons in the rat brain by R-(-)-1-(benzofuran-2-yl)-2- propylaminopentane, (-)-BPAP. Life Sci 71:2137-2144.
54. Larsen JP, Boas J, Erdal JE (1999) Does selegiline modify the progression of early Parkinson's disease? Results from a fiveyear study. the Norwegian-Danish Study Group. Eur J Neurol 6:539-547. (Pubitemid 30028808)
55. Löscher W, Lehmann H (1996) L-Deprenyl (selegiline) exerts anticonvulsant effects against different seizure types in mice. J Pharmacol Exp Ther 227:1410-1417. (Pubitemid 27167153)
56. Mann JJ, Gershon S (1980) A selective monoamine oxidase-B inhibitor in endogenous depression. Life Sci 26:877-882.
57. Martini E, Pataky I, Szilágyi K, Venter V (1987) Brief information on an early phase-II study with (-)deprenyl in demented patients. Pharmacopsychiatry 20:256-257.
58. Maruyama W, Yi H, Takahashi T, Shimazu S, Ohde H, Yoneda F, Iwasa K, Naoi M (2004) Neuroprotective function of R-(-)-1-(benzofuran-2-yl)-2- propylaminopentane, [R-(-)-BPAP], against apoptosis induced by N-methyl(R)salsolinol, an endogenous dopaminergic neurotoxin, in human dopaminergic neuroblastoma SH-SY5Y cells. Life Sciences 75:107-117.
59. Mendlewicz J, Youdim MBH (1983) L-deprenyl, a selective monoamine oxidase-type B inhibitor, in the treatment of depression: a double-blind evaulation. Br J Psychiatry 142:508-11
60. Milgram MW, Racine RJ, Nellis P, Mendoca A, Ivy GO (1990) Maintenance on L-(-)deprenyl prolongs life in aged male rats. Life Sci 47:415-420.
61. Miklya I, Gaszner P (2004) Treatment possibilities of Alzheimer's diasease. Neuropsychopharmacol Hung 6:200-209.
62. Miklya I (2007) A (-)-deprenil szerepe az agytörzsi enhancer reguláció felfedezésében. Neuropsychopharmacol Hung Suppl. 9:37-42.
63. Miklya I (2009) Az agymucombining double acute accentködés korfüggocombining double acute accent hanyatlásának lassítása (-)-deprenil (Selegilin, Jumex) profilaktikus adagolásával. A 25 éves Knoll javaslat mai nemzetközi megítélése és tanulságai. Neuropsychopharmacol Hung 11:217-225.
64. Monteverde A, Gnemmi P, Rossi F, Monteverde A, Finali GC (1990) Selegiline in the treatment of mild to moderate Alzheimer-type dementia. Clin Ther 12:315-322.
65. Muller T, Kuhn W, Kruger R, Przuntec H (1998) Selegiline as immunostimulant: a novel mechanism of action. J Neurotransm Suppl 52:321-328.
66. Myttyla VV, Sotaniemi KA, Vourinen JA, Heinonen EH (1992) Selegiline as initial treatment in de novo parkinsonian patients. Neurology 42:339-343.
67. Ohta K, Ohta M, Mizuta I, Fujinami A, Shimazu S, Sato N, Yoneda F, Hayashi K, Kuno S (2002) The novel catecholaminergic and serotonergic activity enhancer R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane up-regulates neurotrophic factor synthesis in mouse astrocytes. Neurosci Lett 328:205-208.
68. Parkinson Study Group (1989) Effect of (-)deprenyl on the progression disability in early Parkinson's disease. New Engl J Med 321:1364-1371.
69. Parkinson Study Group (1993) Effect of tocopherol and (-) deprenyl on the progression of disability in early Parkinson's disease. New Engl J Med 328:176-183.
70. Parkinson Study Group (1996) Impact of deprenyl and tocopherol treatment of Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 39:37-45.
71. Parnetti L (1995) Clinical pharmacokinetics of drugs for Alzheimer's disease. Clin Pharmakokinet 29:110-129.
72. Quitkin FM, Liebowitz MR, Stewart JW, McGrath PJ, Harrison W, Rabkin JG, Markowitz J, Davies SO (1984) L-Deprenyl in atypical depressives. Arch Gen Psychiatry 41:777-781.
73. Rapaport A, Stein D, Schwartz M, Levin J, Stier S, Elizur A, Rabey JM (1999) A trial of L-deprenyl for the treatment of neuroleptic-induced parkinsonism. J Neural Transm 106:911-918.
74. Ricci A, Mancini M, Strocchi P, Bongrani S, Bronzetti E (1992) Deficits in cholinergic neurotransmission markers induced by ethylcholine mustard aziridium (AF64A) in the rat hippocampus: sensitivity to treatment with the monoamine oxidase-B inhibitor L-deprenyl. Drug Exp Clin Res 18:163-171.
75. Rinne JO, Röyttä M, Paljärvi L, Rummukainen J, Rinne UK (1991) Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson's disease. Neurology 41:859-861.
76. Ruehl WW, Entriken TL, Muggenberg BA, Bruyette DS, Griffith WG, Hahn FF (1997) Treatment with L-deprenyl prolongs life in elderly dogs. Life Sci 61:1037-1044.
77. Salo PT, Tatton WG (1992) Deprenyl reduces the death of motoneurons caused by axotomy. J Neurosci Res 31:394-400.
78. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. New Engl J Med 336:1216-1222.
79. Shimazu S, Tanigawa A, Sato N, Yoneda F, Hayashi K, Knoll J (2003) Enhancer substances: Selegiline and R-(-)-1-(benzofuran-2-yl)-2- propylaminopentane, [(-)-BPAP] enhance the neurotrophic factor synthesis on cultured mouse astrocytes. Life Sci 72:2785-2792.
80. Stoll S, Hafner U, Kranzlin B, Muller WE (1997) Chronic treatment of Syrian hamsters with low-dose selegiline increases lifespan in females but not males. Neurobiol Aging 18:205-211.
81. Szende B, Magyar K, Szegedi Zs (2000) Apoptotic and antiapoptotic effect of (-)-deprenyl and (-)-desmethyl-deprenyl on human cell lines. Neurobiology 8:249-255.
82. Tariot PN, Cohen RM, Sunderland T, Newhouse PA, Yount D, Mellow AM (1987) L-(-)Deprenyl in Alzheimer's disease. Arch Gen Psychiatry 44:427-433.
83. Tatton WG, Ju WY, Holland DP, Tai C, Kwan M (1994) (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 63:1572-1575. (Pubitemid 24299550)
84. Tatton WG, Chalmers-Redman RM (1996) Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegenaration. Neurology Suppl 3:S171-183.
85. Tatton WG, Wadia JS, Ju WY, Chalmers-Redman RM, Tatton NA (1996) (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. J Neural Transm Suppl 48:45-59.
86. Tetrud JW, Langston JW (1989) The effect of (-)deprenyl (selegiline) on the natural history of Parkinson's disease. Science 245:519-522. (Pubitemid 19204003)
87. ThyagaRajan S, Madden KS, Kalvass JC, Dimitrova SS,Felten SY, Felten DL (1998) L-deprenyl-induced increase in IL-2 and NK cell activity accompanies restoration of noradrenergic nerve fibres in the spleens of old F344 rats. J Neuroimmunol 92:9-21.
88. ThyagaRajan S, Felten DL (2002) Modulation of neuroendocrineimmune signalling by L-deprenyl and L-desmethyldeprenyl in aging and mammary cancer. Mech Aging Dev 123:1056-1079. (Pubitemid 34603090)
89. Tsunekawa H, Noda Y, Miyazaki M, Yoneda F, Nabeshima T, Wang D (2008) Effects of (R)-(-)-1-(benzofura-2-yl)-2-propylaminopentane hydrochloride [(-)-BPAP] in animal models of mood disorders. Behav Brain Res 189:107-116.
90. Yoneda F, Moto T, Sakae M, Ohde H, Knoll B, Miklya I, Knoll J (2001) Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2- propylaminopentane, (-)BPAP, a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. Bioorg Med Chem 9:1197-1212. (Pubitemid 32453280)
91. Varga E, Tringer L (1965) Clinical trial of a new type of promptly acting psychoenergetic agent (phenyl-isopropylmethyl-propinylamine HCl, E-250). Acta Med Acad Sci Hung 23:289-295.